an vrisme aorte abdominale aaa consensus canadien acc aha ssvq 2006
Download
Skip this Video
Download Presentation
Anévrisme aorte abdominale (AAA) Consensus canadien - ACC/AHA - SSVQ - 2006

Loading in 2 Seconds...

play fullscreen
1 / 20

Anévrisme aorte abdominale (AAA) Consensus canadien - ACC/AHA - SSVQ - 2006 - PowerPoint PPT Presentation


  • 182 Views
  • Uploaded on

Anévrisme aorte abdominale (AAA) Consensus canadien - ACC/AHA - SSVQ - 2006. Définition et histoire naturelle Dépistage Interventions. André Roussin MD, FRCP Laboratoire de médecine vasculaire, Hôpital Notre-Dame, CHUM Professeur adjoint, Université de Montréal. .org.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Anévrisme aorte abdominale (AAA) Consensus canadien - ACC/AHA - SSVQ - 2006' - favian


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
an vrisme aorte abdominale aaa consensus canadien acc aha ssvq 2006
Anévrisme aorte abdominale (AAA)Consensus canadien - ACC/AHA - SSVQ - 2006
  • Définition et histoire naturelle
  • Dépistage
  • Interventions

André Roussin MD, FRCP

Laboratoire de médecine vasculaire, Hôpital Notre-Dame, CHUM

Professeur adjoint, Université de Montréal

.org

Can J Cardiol 2005; 21(12): 997-1006

www.ccs.ca

disclosures divulgations andr roussin md
Disclosures - DivulgationsAndré Roussin MD

Speaker and/or Advisory board member and/or Research funds

  • AstraZeneca
  • Bristol Myers Squibb
  • Merck Frost Schering
  • Pfizer Canada Inc.
  • sanofi aventis
aaa d finition et pr valence
AAADéfinition et prévalence

AAA : Diamètre > 3 cm (AP en général)

ACC/AHA 2005

aaa examen physique sensibilit pour le d pistage
AAAExamen physique: sensibilité pour le dépistage
  • Sensibilité globale: 68%
    • 61% si diam. 3.0 - 3.9 cm
    • 69% si diam. 4.0 - 4.9 cm
    • 82% si diam > 5.0 cm
    • 91% si TT < 100 cm
    • 53% si TT > 100 cm
    • 100% si diam > 5.0 cm et TT < 100 cm

Fink H A et al. Arch Int Med 2000; 160: 833 - 836

aaa et an vrismes des extr mit s histoire naturelle g n rale
AAA et anévrismes des extrémitésHistoire naturelle générale
  • AAA: rarement
    • Thromboembolie
    • Compression ou érosion de structures adjacentes
  • Anévrismes extrémités
    • Thromboembolie
    • Thrombose
  • AAA : principalement
    • Expansion
      • < 4mm/an
        • Si < 4 cm
      • 4 - 5 mm/an
        • Si 4 - 6 cm
    • Rupture
aaa 5 5 cm risque de rupture us va study
AAA ≥ 5.5 cmRisque de rupture: US VA Study

Consensus canadien MAP CCS 2005

aaa en fonction du sexe risque de rupture s rie de kingston ontario
AAA en fonction du sexeRisque de rupture: série de Kingston, Ontario

Consensus canadien MAP CCS 2005

aaa d pistage consensus am ricain 2004
AAADépistage: Consensus américain 2004

Abdominal aortic aneurysm can easily be missed, especially in obese patients, so that echography is the preferred method of diagnosis in high-risk patients, such as men aged 60 to 85 years, women aged 60 to 85 years with cardiovascular risk factors and men and women older than 50 years with a family history of AAA

Kent KC. Screening for abdominal aortic aneurysm: A consensus statement.

J Vasc Surg 2004; 39: 267-269

aaa d pistage usptf 2005
AAADépistage : USPTF 2005

The USPSTF found good evidence that screening for AAA and surgical repair of large AAAs ( 5.5 cm) in men age 65 to 75 years who have ever smoked (current and former smokers) leads to decreased AAA-specific mortality.

There is good evidence that abdominal ultrasonography, performed in asetting with adequate quality assurance (…), is an accurate screening test for AAA.

Ann Intern Med. 2005; 142:198-202.

aaa suivi et intervention
AAASuivi et Intervention

> 1 cm/an*

* CCS 2005

Sakalihasan N et al. Lancet 2005; 365: 1577-89

canadian cardiovascular society consensus conference 2005 peripheral arterial disease
Canadian Cardiovascular Society Consensus Conference 2005Peripheral Arterial Disease

Beth ABRAMSON, Toronto

Sonia ANAND, Hamilton

Tom FORBES, London

Anil GUPTA ,Brampton

Ken HARRIS, London

Vic HUCKELL, Vancouver

Asad JUNAID, Winnipeg

Tom LINDSAY, Toronto

Finlay McALISTER, Edmonton

Andre ROUSSIN, Montreal

Jacqueline SAW, Vancouver

Koon TEO, Hamilton

A. G TURPIE, Hamilton

Subodh VERMA, Toronto

aaa traitement m dical
AAATraitement médical
  • Traitement des facteurs de risque
    • Tabagisme surtout
  • B-Bloqueurs pour les AAA > 5 cm ?
    • Inefficaces pour AAA < 5 cm
    • Marfan: diminution des complications Ao.
  • IECA ? (selon observation de cohorte)
    • Réduction risque rupture: RRR ajusté 0.83
    • Pas d’effet par autres Tx HTA y compris BRA
  • Bloqueurs JNK et/ou MMP 2 - 8 - 9
aaa le r le de jnk et des mmp
AAALe rôle de JNK et des MMP

Verma S, Lindsay T. NEJM 2006; 354: 2067-8

aaa le r le de jnk et des mmp1
AAALe rôle de JNK et des MMP

Verma S, Lindsay T. NEJM 2006; 354: 2067-8

sources d information
Sources d\'information

ACC/AHA 2005 guidelines on PAD

www.acc.org

www.americanheart.org

.org

Consensus canadien 2005 MAP

Can J Cardiol 2005; 21(12): 997-1006

www.ccs.ca

ad